Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
ADVERTISEMENT FEATUREAdvertiser retains sole responsibility for the content of this article
Exicure uses its proprietary spherical nucleic acids to treat disease at its genetic source
The clinical-stage biotechnology company has pioneered the development of 3D spherical nucleic acids to treat a broad range of inflammatory disorders affecting multiple organs in the body.